Israeli Researchers Want ImClone To Pay Royalties

Law360, New York (November 2, 2006, 12:00 AM EST) -- ImClone Systems Inc. should pay restitution and royalties and be required to get a license for its popular cancer drug Erbitux from the true inventors of the drug, an attorney for the inventors said Tuesday in a recent court filing.

An attorney for Yeda Research and Development Company Ltd. filed the claim in the U.S. District Court for the Southern District of New York.

Last month, a federal judge ruled that scientists at biopharmaceutical company ImClone Systems Inc. copied the work of three Israeli researchers defended...
To view the full article, register now.